| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | — | — |
| Cost of Revenue | $631K | — | — |
| R&D Expense | $1.3M | — | +62.8% |
| SG&A Expense | $3.8M | — | +29.6% |
| Operating Income | -$4.7M | — | -23.3% |
| Income Tax | $0 | — | — |
| Net Income | -$1.4M | — | +74.1% |
| EPS (Basic) | -$0.04 | — | +88.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $6.7M | -13.9% | +21.0% |
| Accounts Receivable | $181K | +12.4% | — |
| Current Assets | $7.4M | -17.2% | +1.4% |
| Total Assets | $11.9M | -8.1% | +56.8% |
| Current Liabilities | $25.2M | -11.9% | -23.1% |
| Total Liabilities | $25.7M | -11.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.3M | — | -23.4% |
| Investing Cash Flow | -$213K | — | — |
| Financing Cash Flow | $3.4M | — | -54.9% |
| -21.5% |
| Stockholders' Equity | -$13.8M | +13.3% | +45.1% |